Alicia Morgans: Hi. I’m delighted to have here with me today Brenda Martone, a nurse practitioner in the Medical Oncology Group at Northwestern University, a good friend and colleague of mine. Thank you so much for talking with me today. Brenda Martone: Thank you, Alicia. It’s nice to see you. Alicia Morgans: Of course. Well, I wanted to […]
Charles Ryan: Hello. I’m joined today by Professor Morgan Roupret who is a Professor of Urology at the Sorbonne University and works at the Pitié Hospital in Paris. Thank you for joining us. Morgan Roupret: Thank you. Charles Ryan: We’re going to talk about bladder cancers today, your specialty. You have a few things going on […]
Diane Newman: Today I’m going to do a little bit of a show and tell and by that I mean, I have with me, Tessa Huang, who’s a manufacturer of intermittent catheters in mainland China. I met her recently when I visited China, I was teaching urology nurses in the mainland and I came upon her […]
Charles Ryan: Hello. I’m joined today by Professor Morgan Roupret who is a Professor of Urology at the Sorborne University and works at the Pitie Hospital in Paris. Thank you for joining us. Morgan Roupret: Thank you. Charles Ryan: I want to transition now, and I wanted to ask you a little bit about the increase in bladder […]
The aim of the present study was to evaluate the influence of preoperative hydronephrosis and ureteral orifice involvement (UOI) on survival of patients undergoing radical cystectomy (RC) for bladder cancer (BC). A total of 162 patients with BC underwent RC between January 2006 and March 2017. Patients were divided into two groups for both presences […]
The clinical validity and utility of complex biomarkers have not been extensively studied in bladder cancer. Three patients with nonmuscle invasive bladder cancer [1 patient with an exceptional response; complete response (CR) for 30 months] who failed intravesical BCG were evaluated using an NYS CLEP approved assay, Immune Report Card, which measures programmed death-ligand 1 […]
Molecular subtyping of urothelial cancer (UC) has significantly advanced the understanding of bladder tumor heterogeneity and development of prognostic and predictive biomarkers. Evolving evidence across cancers strongly suggests that tumor immunoediting has a profound impact on the behaviour of cancer cells and their adaptation to the co-evolving microenvironment and response to treatment. In alignment with […]
An excess incidence of prostate cancer has been identified among World Trade Center (WTC) responders. In this study, we hypothesized that WTC dust, which contained carcinogens and tumor-promoting agents, could facilitate prostate cancer development by inducing DNA damage, promoting cell proliferation, and causing chronic inflammation. We compared expression of immunologic and inflammatory genes using a […]
To evaluate technical feasibility, oncological and functional outcomes of nerve sparing cystoprostatectomy (NSCP) and prostate capsule sparing cystectomy (PCSC) for the treatment of organ confined bladder cancer at a single referral center. From April 2001 to June 2012, 60 patients underwent PCSC, while 47 were treated with NSCP. Inclusion criteria for PCSC were: fully informed […]
There is uncertainty regarding the oncologic effectiveness and the survival advantage of local treatment (LT) in men with clinically lymph node-positive (cN+) prostate cancer (PCa). To systematically review the current literature comparing oncologic outcomes associated with the use of any form of LT for PCa patients with cN+ disease. A computerized bibliographic search of the […]
